The U.S. Food and Drug Administration (FDA) has accepted Replimune's BLA resubmission for RP1 in combination with nivolumab, which targets advanced melanoma in patients who have not responded to prior ...
Renal cancer mortality and disability worldwide: Insights from the Global Burden of Disease (1990–2021). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback